Medicamen Biotech Limited (531146) Fair Value & Analysis
Healthcare · IN · Market cap ₹4.8B
Fair value as of: Aug 13, 2026
From 17 valuation models · updated 5 days ago
Below-average quality, and screening another 58% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹95.98). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹221.85 – ₹1,192 · fair‑value band ₹74.19 – ₹95.98 · the ₹225.95 price screens above the ₹95.98 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Medicamen Biotech Limited (531146) currently trades at ₹225.95, while our model-based Fair Value estimate is ₹95.98, implying the stock looks roughly 57.5% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Medicamen Biotech Limited generated revenue of ₹1.2B at a net margin of 10.0%. Revenue declined 10.7% year over year. The stock trades on a trailing P/E of 37.5 (as of Jul 4, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹74.19 (bear case) to ₹95.98 (bull case); at ₹225.95, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -58%, 531146 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: DCF Models (₹157.15) versus Dividend Discount (₹14.61). Highest evidence: Residual Income (76).
Notify me when 531146 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 11
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, ointments, and oral rehydration solutions. It also provides oral rehydration solution, mouth wash, and dental care products.
Full company description
Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, ointments, and oral rehydration solutions. It also provides oral rehydration solution, mouth wash, and dental care products. The company was founded in 1993 and is headquartered in New Delhi, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medicamen Biotech Limited reported revenue of ₹1.6B in FY2025 versus ₹1.1B in FY2021, a compound +9.6%/yr. Reported net income was ₹71.1M in FY2025, compounding −12.5%/yr from FY2021.
531146 screens 58% overvalued. Compare with Indoco Remedies Limited →
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹222.50 | ₹96.79 | -56% |
| Anuh Pharma Limited 506260 | ₹77.18 | ₹51.89 | -33% |
| Gufic Biosciences Limited 509079 | ₹421.20 | ₹182.30 | -57% |
| Mangalam Drugs & Organics Limited 532637 | ₹27.95 | ₹18.52 | -34% |
| Coral Laboratories Limited 524506 | ₹579.05 | ₹779.23 | +35% |
| Gennex Laboratories Limited 531739 | ₹9.00 | ₹27.82 | +209% |
| Lactose (India) Limited 524202 | ₹106.25 | ₹130.91 | +23% |
| Beryl Drugs Limited 524606 | ₹23.18 | ₹14.44 | -38% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
Compare Medicamen Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medicamen Biotech Limited (531146) overvalued or undervalued?
What is the fair value of 531146?
What is the quality score of 531146?
What is the revenue of Medicamen Biotech Limited (531146)?
What is the net profit margin of 531146?
Does Medicamen Biotech Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Medicamen Biotech Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.